IGF1 and neoplasm: The clinical relevance of these in vitro findings was confirmed by, for example, an immune-histochemical analysis of pancreatic cancer biopsies that identified activated insulin/IGF receptors expressed in 72% of the patients, which positively correlates with the infiltration of TAMs that secrete IGF-1 and IGF-2 along with tumor stromal myofibroblasts, supporting the chemo-resistance of the tumors [93].